These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 31344662)

  • 1. Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center.
    Chen F; Zuo Y; Li S; Shi J; Wang G; Shu X
    Respir Med; 2019 Aug; 155():127-132. PubMed ID: 31344662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
    Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
    Front Immunol; 2022; 13():879266. PubMed ID: 35603153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease].
    Zou RY; Zhao Q; Tian YQ; Yan X; Qiu XH; Gao YJ; Liu Y; Huang M; Cao M; Dai JH; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):781-790. PubMed ID: 37536988
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.
    Xing X; Li A; Li C
    Respir Med; 2020 Oct; 172():106134. PubMed ID: 32905890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study.
    Dunga SK; Kavadichanda C; Gupta L; Naveen R; Agarwal V; Negi VS
    Rheumatol Int; 2022 Jul; 42(7):1155-1165. PubMed ID: 34050793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
    Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q
    BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 or clinical amyopathic dermatomyositis associated rapidly progressive interstitial lung disease? A case report.
    Cao M; Zhang S; Chu D; Xiao M; Liu X; Yu L; Li J; Huang Y; Fang F
    BMC Pulm Med; 2020 Nov; 20(1):304. PubMed ID: 33213393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
    Ge Y; Li S; Tian X; He L; Lu X; Wang G
    Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
    J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
    Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
    Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
    J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China.
    Wang R; Zhao Y; Qi F; Wu X; Wang Y; Xu Y; Wu Y; Zhang N; Hou H; Sun W; Li X; Wei W
    Clin Rheumatol; 2023 Mar; 42(3):703-709. PubMed ID: 36308573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury].
    Zhang PL; Yang HX; Zhang LN; Ge YP; Peng QL; Wang GC; Lu X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1055-1060. PubMed ID: 34916681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.